首页> 外文会议>Conference on Photonics North >In vitro studies of the efficiency of two-photon activation of photodynamic therapy agents
【24h】

In vitro studies of the efficiency of two-photon activation of photodynamic therapy agents

机译:光动力治疗剂两光子激活效率的体外研究

获取原文
获取外文期刊封面目录资料

摘要

Age related macular degeneration (AMD) is a major cause of severe vision loss in the older population, due to ingrowth of new leaky blood vessels (neovasculature) from the choriocapillaris, which results in destruction of photoreceptors in the fovea and loss of central vision. "Standard" one-photon (1-γ) photodynamic therapy (PDT) using Visudyne(R) is an approved method of AMD treatment but has the potential to damage healthy tissues lying above and below the neovasculature due to photosensitizer accumulation and its wide-beam 1-γ excitation. Highly-targeted two-photon (2-γ) excitation may avoid this, since, due to its non-linear intensity dependence, the probability of 2-γ excitation is greatest in the focal plane, which intrinsically avoids out-of-focus damage to healthy tissues. The aim of the present study is to evaluate the 2-γ efficiency of Visudyne and to compare it to the archetypal photosensitizer Photofrin(R). Since neovascular endothelium is targeted in AMD, an endothelial cell line (YPEN-1) was selected as the in vitro model. 2-γPDT was delivered using tightly focused ~300 fs laser pulses from a Ti:sapphire laser operating at 850 nm with 90 MHz pulse repetition rate. An assay was developed for quantification of the cellular damage using the permeability stain Hoechst 33258 and the viability stain SYTOX. Visudyne (LD50= dose to kill 50% of cells: 500 J/cm2, 10 M, 7.2 μg/ml) was about an order of magnitude more effective than Photofrin (LD50 : 7500 J/cm2, ~42 μM, 25 μg/ml). We also demonstrate for the first time the quadratic dependence of the cellular response to 2-γPDT. This in vitro work will lead to the design of optimized in vivo studies in animal models of AMD.
机译:年龄相关的黄斑变性(AMD)是老年人口严重视力丧失的主要原因,由于浓毛细血管的新泄漏血管(新生血管系统),这导致毁灭性的光感受器和中央视觉丧失。使用Visudyne(R)的“标准”单光子(1-γ)光动力治疗(PDT)是AMD治疗的批准方法,但由于光敏剂积累和其广泛 - 具有损害伴随的健康组织和下方的健康组织。光束1-γ激发。高靶向的双光子(2-γ)激发可以避免这一点,因为由于其非线性强度依赖性,2-γ激励的概率在焦平面中最大,因此焦平面最大,其本质上避免了焦点损坏健康组织。本研究的目的是评估Visudyne的2-γ效率,并将其与拟型光敏剂光素(R)进行比较。由于新生血管内皮靶向AMD,因此选择内皮细胞系(YPEN-1)作为体外模型。使用从Ti的Ti:300 FS激光脉冲从Ti的紧密聚焦〜300 fs激光脉冲递送2-γpdt:使用90 MHz脉冲重复率为850nm的蓝宝石激光。开发了测定,用于使用渗透性染色Hoechst 33258和活力染色Sytox定量细胞损伤。 Visudyne(LD50 =杀死50%细胞的剂量:500J / cm2,10μm,7.2μg/ ml)大约比Photofrin更有效的数量级(LD50:7500J / cm 2,〜42μm,25μg/ ml)。我们还向第一次证明了蜂窝响应对2-γPDT的二次依赖性。这种体外工作将导致在AMD的动物模型中的体内研究优化设计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号